Improved graft survival in highly sensitized patients undergoing renal transplantation after the introduction of a clinically validated flow cytometry crossmatch.

Hdl Handle:
http://hdl.handle.net/10147/127612
Title:
Improved graft survival in highly sensitized patients undergoing renal transplantation after the introduction of a clinically validated flow cytometry crossmatch.
Authors:
Limaye, Sandhya; O'Kelly, Patrick; Harmon, Grainne; O'Neill, Derek; Dorman, Anthony M; Walshe, Joseph; Donohoe, John; Little, Dilly; Conlon, Peter J; Keogan, Mary T
Affiliation:
National Histocompatibility and Immunogenetics Service for Solid Organ Transplantation, Beaumont Hospital, Dublin, Ireland.
Citation:
Improved graft survival in highly sensitized patients undergoing renal transplantation after the introduction of a clinically validated flow cytometry crossmatch. 2009, 87 (7):1052-6 Transplantation
Journal:
Transplantation
Issue Date:
15-Apr-2009
URI:
http://hdl.handle.net/10147/127612
DOI:
10.1097/TP.0b013e31819d17b0
PubMed ID:
19352127
Abstract:
Flow cytometric techniques are increasingly used in pretransplant crossmatching, although there remains debate regarding the clinical significance and predictive value of donor-specific antibodies detected by flow cytometry. At least some of the discrepancies between published studies may arise from differences in cutoffs used and lack of standardization of the test.; We selected cut-off values for pretransplant flow cytometric crossmatching (FCXM) based on the correlation of retrospective results with the occurrence of antibody-mediated rejection. The impact on long-term renal graft survival of prospective FCXM was determined by comparing graft survival between patients crossmatched with complement-dependent cytotoxicity (CDC) only with those prospectively crossmatched with both CDC and FCXM.; Chosen cut-off values gave a positive predictive value of FCXM for antibody-mediated rejection of 83%, and a negative predictive value of 90%. After the introduction of prospective B- and T-cell crossmatching by flow cytometry in addition to CDC in our center, there was a significant improvement in renal graft survival in highly sensitized patients (P=0.017). Four-year graft survival in highly sensitized patients after the introduction of FCXM was 89%, which did not differ significantly from that seen in nonsensitized patients (93%; P=0.638).; Our data demonstrate that prospective FCXM improves renal transplant outcome in highly sensitized patients, provided that cut-off values are carefully validated and results interpreted in the context of sensitization history and antibody screening results.
Item Type:
Article
Language:
en
MeSH:
B-Lymphocytes; Flow Cytometry; Graft Survival; Histocompatibility Testing; Humans; Immunization; Isoantibodies; Kidney Transplantation; Predictive Value of Tests; Survival Analysis; Survivors; T-Lymphocytes
ISSN:
1534-6080

Full metadata record

DC FieldValue Language
dc.contributor.authorLimaye, Sandhyaen
dc.contributor.authorO'Kelly, Patricken
dc.contributor.authorHarmon, Grainneen
dc.contributor.authorO'Neill, Dereken
dc.contributor.authorDorman, Anthony Men
dc.contributor.authorWalshe, Josephen
dc.contributor.authorDonohoe, Johnen
dc.contributor.authorLittle, Dillyen
dc.contributor.authorConlon, Peter Jen
dc.contributor.authorKeogan, Mary Ten
dc.date.accessioned2011-04-07T08:29:06Z-
dc.date.available2011-04-07T08:29:06Z-
dc.date.issued2009-04-15-
dc.identifier.citationImproved graft survival in highly sensitized patients undergoing renal transplantation after the introduction of a clinically validated flow cytometry crossmatch. 2009, 87 (7):1052-6 Transplantationen
dc.identifier.issn1534-6080-
dc.identifier.pmid19352127-
dc.identifier.doi10.1097/TP.0b013e31819d17b0-
dc.identifier.urihttp://hdl.handle.net/10147/127612-
dc.description.abstractFlow cytometric techniques are increasingly used in pretransplant crossmatching, although there remains debate regarding the clinical significance and predictive value of donor-specific antibodies detected by flow cytometry. At least some of the discrepancies between published studies may arise from differences in cutoffs used and lack of standardization of the test.-
dc.description.abstractWe selected cut-off values for pretransplant flow cytometric crossmatching (FCXM) based on the correlation of retrospective results with the occurrence of antibody-mediated rejection. The impact on long-term renal graft survival of prospective FCXM was determined by comparing graft survival between patients crossmatched with complement-dependent cytotoxicity (CDC) only with those prospectively crossmatched with both CDC and FCXM.-
dc.description.abstractChosen cut-off values gave a positive predictive value of FCXM for antibody-mediated rejection of 83%, and a negative predictive value of 90%. After the introduction of prospective B- and T-cell crossmatching by flow cytometry in addition to CDC in our center, there was a significant improvement in renal graft survival in highly sensitized patients (P=0.017). Four-year graft survival in highly sensitized patients after the introduction of FCXM was 89%, which did not differ significantly from that seen in nonsensitized patients (93%; P=0.638).-
dc.description.abstractOur data demonstrate that prospective FCXM improves renal transplant outcome in highly sensitized patients, provided that cut-off values are carefully validated and results interpreted in the context of sensitization history and antibody screening results.-
dc.language.isoenen
dc.subject.meshB-Lymphocytes-
dc.subject.meshFlow Cytometry-
dc.subject.meshGraft Survival-
dc.subject.meshHistocompatibility Testing-
dc.subject.meshHumans-
dc.subject.meshImmunization-
dc.subject.meshIsoantibodies-
dc.subject.meshKidney Transplantation-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshSurvival Analysis-
dc.subject.meshSurvivors-
dc.subject.meshT-Lymphocytes-
dc.titleImproved graft survival in highly sensitized patients undergoing renal transplantation after the introduction of a clinically validated flow cytometry crossmatch.en
dc.typeArticleen
dc.contributor.departmentNational Histocompatibility and Immunogenetics Service for Solid Organ Transplantation, Beaumont Hospital, Dublin, Ireland.en
dc.identifier.journalTransplantationen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.